These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 29248177)

  • 21. A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
    Sasidharakurup H; Melethadathil N; Nair B; Diwakar S
    OMICS; 2017 Aug; 21(8):454-464. PubMed ID: 28816645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuronal pathology in Parkinson's disease.
    Schulz JB; Falkenburger BH
    Cell Tissue Res; 2004 Oct; 318(1):135-47. PubMed ID: 15365812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can mesenchymal stem cells reduce vulnerability of dopaminergic neurons in the substantia nigra to oxidative insult in individuals at risk to Parkinson's disease?
    Datta I; Bhonde R
    Cell Biol Int; 2012 Jul; 36(7):617-24. PubMed ID: 22417707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopaminergic Neuronal Differentiation from the Forebrain-Derived Human Neural Stem Cells Induced in Cultures by Using a Combination of BMP-7 and Pramipexole with Growth Factors.
    Yang H; Wang J; Wang F; Liu X; Chen H; Duan W; Qu T
    Front Neural Circuits; 2016; 10():29. PubMed ID: 27147976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
    Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
    Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
    González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
    J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of mouse models of Parkinson's disease.
    Bobela W; Zheng L; Schneider BL
    Curr Protoc Mouse Biol; 2014 Sep; 4(3):121-39. PubMed ID: 25723963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.
    Sulzer D
    Trends Neurosci; 2007 May; 30(5):244-50. PubMed ID: 17418429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ferroptosis and cell death mechanisms in Parkinson's disease.
    Guiney SJ; Adlard PA; Bush AI; Finkelstein DI; Ayton S
    Neurochem Int; 2017 Mar; 104():34-48. PubMed ID: 28082232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcription Factors: Potential Cell Death Markers in Parkinson's Disease.
    Wang R; Yang S; Nie T; Zhu G; Feng D; Yang Q
    Neurosci Bull; 2017 Oct; 33(5):552-560. PubMed ID: 28791585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
    Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
    Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A WNT1-regulated developmental gene cascade prevents dopaminergic neurodegeneration in adult En1(+/-) mice.
    Zhang J; Götz S; Vogt Weisenhorn DM; Simeone A; Wurst W; Prakash N
    Neurobiol Dis; 2015 Oct; 82():32-45. PubMed ID: 26049140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease.
    Nyholm D
    Parkinsonism Relat Disord; 2007 Sep; 13 Suppl():S13-7. PubMed ID: 17707679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease?
    Herrera A; Muñoz P; Steinbusch HWM; Segura-Aguilar J
    ACS Chem Neurosci; 2017 Apr; 8(4):702-711. PubMed ID: 28233992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell death caused by the synergistic effects of zinc and dopamine is mediated by a stress sensor gene Gadd45b - implication in the pathogenesis of Parkinson's disease.
    Yang TC; Wu PC; Chung IF; Jiang JH; Fann MJ; Kao LS
    J Neurochem; 2016 Oct; 139(1):120-33. PubMed ID: 27385273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Striatal dopaminergic neurons are lost with Parkinson's disease progression.
    Porritt MJ; Kingsbury AE; Hughes AJ; Howells DW
    Mov Disord; 2006 Dec; 21(12):2208-11. PubMed ID: 17029264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease.
    Tripathy D; Chakraborty J; Mohanakumar KP
    Free Radic Res; 2015; 49(9):1129-39. PubMed ID: 25968946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.